Abstract
Many neurodegenerative diseases are diseases of high unmet medical need. Tauopathies such as Alzheimer’s disease, progressive supranuclear palsy, and frontotemporal lobar degeneration cause intracellular accumulation of tau aggregates due to abnormal phosphorylation of tau protein, which then propagate through neurons, resulting in neurodegeneration. Even if a drug that inhibits the accumulation of tau aggregates in neurons is found, it will be difficult to develop an effective therapeutic agent to prevent and fundamentally treat the progression of neurodegenerative diseases unless a DDS technology that can efficiently deliver the drug into the neurons and transfer the drug across neurons is developed. In this paper, the authors describe the development of a nose-to-brain system that is applicable to neurodegenerative diseases and can deliver neuropeptides to the site of action more efficiently than intraventricular administration via intra-neuronal axonal transfer and show central effects.
